Edwards Lifesciences Corporation $EW Shares Bought by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors LP increased its stake in Edwards Lifesciences by 9.1% in Q3, buying 305,854 shares to hold 3,683,748 shares (about 0.63% of the company) valued at roughly $286.5 million.
• Corporate insiders have been reducing exposure: VP Donald E. Bobo Jr. sold 11,340 shares at an average of $85.93 and CFO Scott B. Ullem sold 7,700 shares at $84.47, with insiders offloading 79,144 shares (~$6.69M) in the last 90 days and now owning 1.29% of the stock.
• Edwards reported quarterly EPS of $0.58 (below estimates of $0.62) and revenue of $1.57B (up 13.3% YoY), set Q1 2026 guidance of $0.70–$0.76 EPS, and carries a market cap of $47.46B with an average analyst rating of “Moderate Buy” and a $96.14 price target.

Dimensional Fund Advisors LP raised its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 9.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,683,748 shares of the medical research company's stock after buying an additional 305,854 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.63% of Edwards Lifesciences worth $286,470,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. True Wealth Design LLC raised its position in Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company's stock valued at $28,000 after purchasing an additional 259 shares during the last quarter. NewSquare Capital LLC grew its position in Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company's stock worth $29,000 after purchasing an additional 134 shares during the last quarter. Hantz Financial Services Inc. grew its position in Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company's stock worth $29,000 after purchasing an additional 164 shares during the last quarter. Rakuten Securities Inc. increased its stake in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company's stock valued at $29,000 after purchasing an additional 302 shares during the period. Finally, Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at about $30,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 11,340 shares of the company's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $85.93, for a total transaction of $974,446.20. Following the transaction, the vice president directly owned 21,266 shares of the company's stock, valued at $1,827,387.38. This represents a 34.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares of the company's stock, valued at $3,370,184.06. This represents a 16.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 79,144 shares of company stock worth $6,685,688. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $81.71 on Friday. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The stock has a 50 day simple moving average of $82.56 and a 200-day simple moving average of $81.45. The company has a market cap of $47.46 billion, a price-to-earnings ratio of 44.65, a price-to-earnings-growth ratio of 2.19 and a beta of 0.93. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts' consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company's revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on EW shares. Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the stock a "hold" rating in a research note on Wednesday, December 17th. BTIG Research restated a "buy" rating and issued a $103.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. TD Cowen raised Edwards Lifesciences from a "hold" rating to a "buy" rating in a research report on Friday, January 9th. Piper Sandler reiterated an "overweight" rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, UBS Group reissued a "neutral" rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average price target of $96.14.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.